Hepatology International

, Volume 7, Supplement 2, pp 833–841

Pharmacological agents for nonalcoholic steatohepatitis

Authors

  • Maeva Guillaume
    • Service d’Hépatologie et Gastro-entérologie, INSERM 1048 and Université Paul Sabatier, Hôpital PurpanCentre Hospitalier Universitaire de Toulouse
    • Service d’Hépatologie et Gastro-entérologieHôpital Purpan
    • INSERM U938, Hospital Pitié SalpêtrièreCdR Saint-Antoine and Université Pierre et Marie Curie
    • Service d’Hépatologie et Gastro-entérologieHôpital Pitié-Salpêtrière
Review Article

DOI: 10.1007/s12072-013-9482-8

Cite this article as:
Guillaume, M. & Ratziu, V. Hepatol Int (2013) 7: 833. doi:10.1007/s12072-013-9482-8
  • 150 Views

Abstract

The rationale for specific pharmacologic therapy in nonalcoholic steatohepatitis (NASH) is determined by the potential for disease progression and the difficulties, in many patients, to successfully implement diet and lifestyle changes in the long term. Because they correct insulin resistance, insulin-sensitizing agents are attractive candidates for the treatment of NASH. However, two randomized studies have shown that vitamin E, despite having no effect on insulin sensitivity, achieves interesting histological and biochemical efficacy. This review provides an insight into the therapeutic efficacy and safety issues of different pharmacological agents tested in human NASH.

Keywords

SteatohepatitisFibrosisSteatosisGlitazonesVitamin EUrsodesoxycholic acidInsulin resistanceOxidative stressInsulin sensitizers

Copyright information

© Asian Pacific Association for the Study of the Liver 2014